'Xtandi' has virtually overcome its difference in drug price with ‘Erleada.’

Dailpharm’s coverage found out that Astellas Pharma Korea recently reached a final agreement with the National Health Insurance Service to negotiate the drug price for its prostate cancer treatment drug Xtandi (enzalutamide) to convert its indication for metastatic hormone-sensitive prostate cancer (mHSPC) to full reimbursement. The conversion will likely be made in November.

Through the negotiations, the company was finally able to close the out-of-pocket coinsurance difference between its Xtandi and Janssen Korea’s ‘Erleada (apalutamide).’

Controversy was raised over Xtandi’s coinsurance